DEF: NanoVibronix Seeks Shareholder Approval for Key Proposals

NanoVibronix calls 2025 Annual Meeting for votes on board, auditor, incentive plan, and private placement share issuance.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on December 4, 2025, at 10:00 a.m. Eastern Time, with the record date set as October 27, 2025.
• Key proposals include the election of five director nominees, ratification of Kost Forer Gabbay & Kasierer (E&Y) as the independent registered public accounting firm for fiscal year 2025, and approval of an amendment to the 2024 Long-Term Incentive Plan.
• The proposed amendment to the 2024 Long-Term Incentive Plan seeks to increase the total number of shares authorized for issuance by an additional 1,200,000, bringing the total to 1,205,454 shares.
• Stockholder approval is also sought for the issuance of shares underlying convertible preferred stock and warrants from a July 2025 private placement, which could exceed 19.99% of common stock outstanding, to comply with Nasdaq Listing Rule 5635(d).
• The July 2025 private placement generated approximately $8.8 million in gross proceeds through the issuance of Series H Convertible Preferred Stock and warrants.
• Brian Murphy resigned as Chief Executive Officer on June 4, 2025, and Doron Besser, M.D., was appointed as the new CEO on the same date.
• The company reported net losses of $(3,705) thousand in 2024, $(3,711) thousand in 2023, and $(5,448) thousand in 2022.
• The former independent auditor, Zwick CPA, PLLC, included an explanatory paragraph in its reports for fiscal years 2024 and 2023, indicating substantial doubt about the company's ability to continue as a going concern.
• Management identified material weaknesses in the design and effectiveness of internal control over financial reporting for the fiscal years ended December 31, 2024, and 2023.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including recurring net losses and a 'going concern' warning from its former auditor. While a capital raise was completed, it involved substantial potential dilution for existing shareholders, indicating a challenging financing environment. Material weaknesses in internal controls further undermine confidence. Despite new management and board members, the fundamental financial health and operational risks are major concerns.

Positives

• Doron Besser, M.D., was appointed Chief Executive Officer, bringing over two decades of leadership experience in medical device innovation and strategic commercialization.
• New board nominees, including David Johnson (proposed Chairman), Nino Pionati, and Alison Geiger Burgett, bring extensive experience in medical technology, healthcare executive leadership, and finance.
• The separation of the Chairman and Chief Executive Officer roles is maintained, reinforcing board independence and oversight of the company's business and affairs.
• A private placement in July 2025 successfully raised approximately $8.8 million in gross proceeds, providing additional funds for general corporate purposes.
• The proposed amendment to the 2024 Long-Term Incentive Plan aims to enhance the company's ability to attract and retain key employees, contractors, and outside directors through equity awards.

Negatives

• The company reported recurring net losses: $(3,705) thousand in 2024, $(3,711) thousand in 2023, and $(5,448) thousand in 2022.
• The former independent auditor, Zwick CPA, PLLC, included an explanatory paragraph in its reports for fiscal years ended December 31, 2024, and 2023, stating substantial doubt about the company's ability to continue as a going concern.
• Management identified deficiencies in the design and effectiveness of internal control over financial reporting that were considered material weaknesses for the fiscal years ended December 31, 2024, and 2023.
• The July 2025 private placement involves significant potential dilution for existing shareholders, as the issuance of underlying shares could exceed 19.99% of common stock outstanding.
• Cumulative Total Shareholder Return (TSR) declined from an assumed $100 investment on December 31, 2022, to $51.30 by December 31, 2024.

Risks

• The potential issuance of shares from the July 2025 private placement (Series H Preferred Stock and Warrants) could significantly dilute current stockholders' percentage ownership and voting power, potentially exceeding 19.99% of common stock outstanding.
• Failure to obtain stockholder approval for the Issuance Proposal would restrict the company from issuing 20% or more of its outstanding common stock to private placement holders and impose limitations on future equity issuances and variable rate transactions.
• The 'going concern' explanatory paragraph from the former independent auditor indicates substantial doubt about the company's ability to continue as an operating entity.
• Material weaknesses in the design and effectiveness of internal control over financial reporting for 2024 and 2023 pose risks to financial reporting integrity and operational efficiency.
• Despite the recent private placement, the company's cash and cash equivalents of approximately $4.0 million as of June 30, 2025, suggest ongoing funding requirements and potential future capital raises.
• The issuance or resale of common stock underlying the Series H Preferred Stock and Warrants could cause the market price of the common stock to decline.
• The increase in issued shares due to the private placement and incentive plan could have an incidental anti-takeover effect, making certain mergers, tender offers, or proxy contests more difficult.

Future Outlook

The company expects the 2024 Long-Term Incentive Plan to be a crucial tool for attracting and retaining key personnel, adapting compensation to a changing business environment, and promoting business success. The recent private placement was undertaken to address immediate cash and funding requirements. The company is committed to seeking ongoing stockholder approval for the private placement share issuance if not initially obtained, and will continue to monitor and manage enterprise-wide risks, including cybersecurity.

Management Comments

• "On behalf of the board of directors, I urge you to submit your vote as soon as possible, even if you currently plan to attend the Annual Meeting online. Thank you for your support of our Company. I look forward to seeing you online at the Annual Meeting via remote communication." Doron Besser, M.D., Chief Executive Officer and Director.
• The Board believes that the operation of the 2024 Long-Term Incentive Plan is a necessary and powerful tool to attract and retain best available personnel, provide additional incentive, and promote business success.
• The Board determined that the July 2025 private placement, which yielded approximately $8.8 million in gross proceeds, was necessary given the company's cash and funding requirements.

Industry Context

NanoVibronix, Inc. operates in the medical technology and biotechnology sectors, which are typically capital-intensive and often require significant investment in R&D, regulatory approvals, and commercialization. The company's need for frequent capital raises, coupled with a 'going concern' warning and internal control weaknesses, reflects challenges common to early commercial-stage companies in these industries. The appointment of a new CEO and board members with strong backgrounds in medical devices and healthcare management suggests a strategic focus on strengthening leadership and operational execution within its niche.

Comparison to Industry Standards

• The company's 'going concern' warning and identified material weaknesses in internal control over financial reporting are significant deviations from best practices for established public companies in the medical technology industry, indicating higher operational and financial risk.
• The substantial dilution associated with the recent private placement, and the need for repeated capital raises, suggests the company may be facing more challenging financing conditions compared to more mature or financially stable industry peers.
• While the appointment of experienced executives and board members is a positive step, the company's financial performance (recurring net losses and declining TSR) lags behind successful, growth-oriented medical technology companies that typically demonstrate revenue growth and a clear path to profitability.

Management Changes

Corporate Governance

Legal Proceedings

• No directors or executive officers, or persons nominated to become a director, have been involved in any bankruptcy petitions, criminal proceedings, or certain court/SEC/CFTC orders in the past ten years.
• The company engaged the law firm FisherBroyles LLP in March 2022 to handle a litigation matter with Protrade Systems, Inc.

Related Party Transactions

• The company paid FisherBroyles LLP $360,000 in legal fees for the year ended December 31, 2023. Aurora Cassirer, a former board member, was a partner at the firm but did not provide legal services to the company.
• The company paid Pierson Ferdinand $69,000 during the year ended December 31, 2024. Aurora Cassirer, a former board member, became a partner at this firm on January 1, 2024, but did not provide legal services to the company.
• On November 29, 2023, the company entered into an option cancellation and release agreement with several directors and officers, paying $1.00 to each for the cancellation of options to purchase an aggregate of 928 shares of common stock.

Stakeholder Impact

• **Shareholders**: Face significant potential dilution from the July 2025 private placement and the proposed increase in shares for the 2024 Long-Term Incentive Plan. The 'going concern' warning and material weaknesses in internal controls pose substantial risks to investment value. The change in CEO and board composition could bring new strategic direction, but the immediate financial outlook is challenging.
• **Employees/Contractors/Outside Directors**: The proposed amendment to the 2024 Long-Term Incentive Plan aims to attract and retain key personnel by increasing the pool of shares available for equity awards, potentially boosting morale and alignment with company performance.
• **Creditors**: The 'going concern' warning from the former auditor may raise concerns about the company's ability to meet its financial obligations. While the recent capital raise provides some liquidity, the underlying financial performance remains a significant risk factor.
• **Customers/Suppliers**: No direct impact is explicitly mentioned, but the company's financial health and strategic direction could indirectly affect its ability to maintain operations, product development, and relationships with customers and suppliers.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on December 4, 2025, to vote on the proposed matters.
• Elect the five nominated directors to the Board for a one-year term.
• Ratify the appointment of Kost Forer Gabbay & Kasierer (E&Y) as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Obtain stockholder approval for the amendment to the 2024 Long-Term Incentive Plan to increase the total number of shares authorized for issuance.
• Obtain stockholder approval for the issuance of shares underlying the convertible preferred stock and warrants from the July 2025 private placement to comply with Nasdaq Listing Rule 5635(d).
• If stockholder approval for the Issuance Proposal is not obtained, the company will call a meeting every four months thereafter to seek such approval until it is obtained or the Series H Preferred Stock is no longer outstanding.
• Publish the voting results in a current report on Form 8-K with the SEC within four business days after the Annual Meeting.
• The next say-on-pay vote and advisory vote on the frequency of executive compensation vote are expected to occur at the annual meeting of stockholders in 2027.

Key Dates

Recommendation

The filing reveals a company in significant financial distress, evidenced by recurring net losses, a 'going concern' warning from its former auditor, and identified material weaknesses in internal controls. While a capital raise was completed, it came with substantial potential dilution for existing shareholders, suggesting the company is raising capital under unfavorable terms. The cumulative total shareholder return has been negative. Despite new management and board members, the fundamental financial health and operational risks are severe, indicating a high probability of continued share price pressure and potential for further value erosion. Investors should consider exiting their positions to mitigate further losses.

Keywords

NanoVibronix, NAOV, Proxy Statement, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, Incentive Plan, Equity Compensation, Private Placement, Convertible Preferred Stock, Warrants, Share Dilution, Capital Raise, Going Concern, Internal Controls, Executive Compensation, Medical Technology, Biotechnology